Date: Aug. 2	Jeh , 2023						
Your Name:	Kai Lu						
Manuscript Title:	HMGB2	upregulation	promotes	the	progression	1 of	hepatoallular
carcinoma celle		the activa	tion of	ZEBI	/ vimentin	axis	
Manuscript number		JG0-23	5 - 447 -	CL			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	2000年1月2日 1月2日 1月2日 1月2日 1月2日 1月2日 1月2日 1月2日	Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
	自由身体的一种特殊。但是	Time frame: pa	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	<u> </u>	
4	Consulting fees	_⊁_None	

resentations, oureaus, t writing or all events or expert or attending and/or travel	_X_None _X_None				
r attending and/or travel	X_None				
and/or travel					
anned, issued or	V None				
on on a Data nitoring Board or oard	None				
oard, society, or advocacy	_x_None				
	None				
drugs, medical	_ x _None				
	_X_None				
3	Board or fiduciary role oard, society, e or advocacy d or unpaid ock options equipment, drugs, medical its or other ncial or non- iterests	Board or fiduciary role oard, society, e or advocacy d or unpaid ock options equipment, drugs, medical its or other micial or non- oterests None	Board o or fiduciary role pard, society, e or advocacy d or unpaid cock options Y None equipment, drugs, medical its or other ncial or non- None	Board of or fiduciary role of or fiduciary role of or advocacy dor unpaid of ock options Part None Part None	or fiduciary role or fiduciary role or dy society, or or advocacy d or unpaid ock options Equipment, drugs, medical of ts or other Incial or non- otherests None

Date: Aug. 20th, 2023
Your Name: Teng Zhow
Manuscript Title: HMGB2 upregulation promotes the progression of hepatocellular
carcinoma cells through the activation of ZEBI/Vimentin axis
Manuscript number (if known): 160-23-447-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
母鄉	(1) X (2) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1	Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
	VI DE STATE OF THE STATE OF THE	Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	
3	Royalties or licenses	_X_None	
4	Consulting fees	None	

5	Payment or honoraria for	X_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
100 E	educational events		ODE TO SELECT THE THE PARTY OF
6	Payment for expert	X_None	
	testimony	·	
7	Support for attending	<u></u> X_None	
	meetings and/or travel		
8	Patents planned, issued or	⊀ None	Substantial distribution in visit debution of the control of the property of the control of the
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	None	
	materials, drugs, medical	0	
	writing, gifts or other		
	services	,	"
13	Other financial or non-	<u></u> X_None	
	financial interests		
		TO A CHECK THE CONTROL OF THE PARTY OF THE P	

Please summarize the above conflict of interest in the following box:

None.			
ο.			

Please place an "X" next to the following statement to indicate your agreement:

Date		02}	
	r Name: Lixue	You G	C. L
	nuscript Title: HMG	R2 Vupregu (extro	in promotes the progression of hepato
	nuscript number (if known):	76	cl (ellu (ar carcinoma (ell through the activation of ZEBI/vimentin axis
rela par to t	ited to the content of your r ties whose interests may be	nanuscript. "Related" me affected by the content ecessarily indicate a bias	I relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment . If you are in doubt about whether to list a
	e following questions apply inuscript only.	to the author's relationsh	ips/activities/interests as they relate to the current
to me	the epidemiology of hyperte edication, even if that medic	ension, you should declare ation is not mentioned in oport for the work reporte	edefined broadly. For example, if your manuscript pertain eall relationships with manufacturers of antihypertensive the manuscript. ed in this manuscript without time limit. For all other iter
		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initi	(e.g., if payments were made to you or to your institution)
1	All support for the present	Name all entities with whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
	manuscript (e.g., funding,	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initi	(e.g., if payments were made to you or to your institution)
1	manuscript (e.g., funding, provision of study materials,	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initi	(e.g., if payments were made to you or to your institution)
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initi	(e.g., if payments were made to you or to your institution)
1	manuscript (e.g., funding, provision of study materials, medical writing, article	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initi	(e.g., if payments were made to you or to your institution)
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initi	(e.g., if payments were made to you or to your institution)
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initi None	(e.g., if payments were made to you or to your institution) al planning of the work
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initi	(e.g., if payments were made to you or to your institution) al planning of the work

any entity (if not indicated

None

None

in item #1 above).

Consulting fees

Royalties or licenses

3

4

	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	_X_None	
7	Support for attending meetings and/or travel	_X_None	
8	Patents planned, issued or pending	_X_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X_None	
11	Stock or stock options	<u>X</u> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	<u>X</u> None	
Г	ease summarize the above c	onflict of interest in the	following box:

Payment or honoraria for

X None

Date: Aug. 21th . 2023	
Your Name: Your land	_ ,
Manuscript Title: HM(1BZ upregulation promotes the progression of hopatocellular cardnoma cells Manuscript number (if known): 160-23-447-00 the activation of ZEB	through
Manuscript number (if known): 160 -13-447- the activation of ZEB	1/ul wench
	0.5065

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	X_None	
0000		Time frame: pa	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None	
3	Royalties or licenses	_X_None	
4	Consulting fees	_X_None	

5	Payment or honoraria for lectures, presentations, speakers bureaus,	_X_None	
	manuscript writing or educational events		
6	Payment for expert testimony	<u>X</u> None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	<u>X</u> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	_X_None	
10	Leadership or fiduciary role in other board, society,	<u>X</u> None	
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	X_None	
12	Receipt of equipment,	_X_None	
	materials, drugs, medical writing, gifts or other services		
13	Other financial or non- financial interests	None	
	Illianciai interests		
Ple	ase summarize the above o	onflict of interest in	the following box:

None.	

2013.8.22	
Date: Xiany Rum	ression of hepatoceller leve carcinoma cells through the cetivation of zers in wenting as
Manuscript Title: time kromoles the mogr	ression of hepatocelles love Carcinoma cells & roughthe activimenting a
Manuscript number (if known):	J60-23-447-Ct.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None None	
3	Royalties or licenses	None	
4	Consulting fees	None	

	Payment or honoraria for	None	
'	ectures, presentations,		
	speakers bureaus,		
The state of the s	manuscript writing or		
A CONTRACTOR OF THE PARTY OF TH	educational events	None	
5	Payment for expert	None	
	testimony		
		1	
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
	PCGB	,	
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10		X None	
10	Leadership or fiduciary role	None	
	in other board, society,		
	group, paid or uppaid		
11	Stock or stock options	None	
-1	Stock of Stock options	None	
12	Peccint of aquinment	V Name	
12	Receipt of equipment, materials, drugs, medical	XNone	
	writing, gifts or other		
	services		
13	Other financial or non-	A NIZZZ	
13	financial interests	None	
No. ii	inidificial interests		

Please summarize the above conflict of interest in the following box:

Wone.		

Please place an "X" next to the following statement to indicate your agreement:

Your Name:	Longjia aii				
Manuscript Title:	HMGB2	upregulation iromote	es the progression of	nepato cellular	carcin
Manuscript number (i	f known):			tja ZE	- 12

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
	1. The state of th	Time frame: pas	et 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X _None	
3	Royalties or licenses	X None	
4	Consulting fees	⊀_None	

5	Payment or honoraria for	X_None	The state of the s
	lectures, presentations, speakers bureaus,	NOTE: THE PROPERTY OF EACH	
	manuscript writing or educational events		A STATE OF THE STA
6.1	Payment for expert testimony	<u>X</u> None	ACTION AND AND AND AND AND AND AND AND AND AN
7	Support for attending meetings and/or travel	X_None	
		office of John College	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_X_None	
11	Stock or stock options	<u>X</u> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	_X_None	
	***		The state of the s

Please summarize the above conflict of interest in the following box:

				MATERIAL TO THE PROPERTY.
Yone.				
the same transfer to the same of the same of				
	A service of the serv			
		e pro escape de maior de la	×	
		er entrope care to be well a	Committee of the Commit	and the second transfer of the second of the

Please place an "X" next to the following statement to indicate your agreement:

Date: Aug with . 2013
Your Narba: Voucie Thana
Manuscript Title: HMGB2 wrogulation promotes the progression of hepatocellular
Manuscript Title: HMGB2 warogulation promotes the progression of hepatocellular Carcinoma cells through the activation of ZEBI/vimentin axis
Manuscript number (if known): 160 - 23 - 447 - CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	X_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	X_None	

5	Payment or honoraria for	X None
5	lectures, presentations,	
	speakers bureaus, manuscript writing or educational events	
6	Payment for expert testimony	X_None
	,	
7	Support for attending meetings and/or travel	None
	Ç.	
8	Patents planned, issued or pending	X None
9	Participation on a Data	None
	Safety Monitoring Board or Advisory Board	
10	Leadership or fiduciary role	X None
10	in other board, society,	
	committee or advocacy group, paid or unpaid	
11	Stock or stock options	_X_None
12	5	J
12	Receipt of equipment, materials, drugs, medical	None
	writing, gifts or other services	
13	Other financial or non-	X None
	financial interests	-/
Ple	ease summarize the above o	conflict of interest in the following box:
	None	
	NONE	